$EVOK
Evoke Pharma Inc

2017 Q3 Form 10-K Financial Statement

#000156459018004725 Filed on March 07, 2018

View on sec.gov

Income Statement

Concept 2017 Q3 2017 Q2 2017
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $980.0K $870.0K $4.090M
YoY Change 18.07% 8.75% 13.93%
% of Gross Profit
Research & Development $2.718M $2.018M $7.137M
YoY Change 102.91% -3.7% 2.67%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.718M $2.890M $11.23M
YoY Change 102.91% -0.28% 6.51%
Operating Profit -$11.23M
YoY Change 6.51%
Interest Expense $2.822K $1.667K $6.519K
YoY Change -102.35% -102.38% -102.43%
% of Operating Profit
Other Income/Expense, Net -$1.541M $1.264M -$1.010M
YoY Change 111.14% -1838.22% -1783.33%
Pretax Income -$5.240M -$1.630M -$12.23M
YoY Change 72.94% -45.12% 13.77%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.243M -$1.626M -$12.23M
YoY Change 73.31% -45.26% 13.77%
Net Earnings / Revenue
Basic Earnings Per Share -$0.34 -$0.11 -$0.82
Diluted Earnings Per Share -$0.34 -$0.13 -$0.90
COMMON SHARES
Basic Shares Outstanding 15.35M 15.34M 14.90M
Diluted Shares Outstanding 15.35M 15.42M 14.95M

Balance Sheet

Concept 2017 Q3 2017 Q2 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.41M $12.56M $7.680M
YoY Change 0.29% 204.12% -14.76%
Cash & Equivalents $10.41M $12.56M $7.680M
Short-Term Investments
Other Short-Term Assets $330.0K $590.0K $250.0K
YoY Change -25.0% 15.69% -10.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.75M $13.14M $7.930M
YoY Change -0.56% 183.19% -14.55%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change 0.0%
Total Long-Term Assets $10.00K $20.00K $10.00K
YoY Change 0.0%
TOTAL ASSETS
Total Short-Term Assets $10.75M $13.14M $7.930M
Total Long-Term Assets $10.00K $20.00K $10.00K
Total Assets $10.76M $13.16M $7.940M
YoY Change -0.46% 183.62% -14.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.720M $1.120M $1.050M
YoY Change 244.0% -11.11% 118.75%
Accrued Expenses $930.0K $760.0K $1.030M
YoY Change 82.35% 52.0% 10.75%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.650M $1.880M $2.070M
YoY Change 162.38% -69.48% 46.81%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $6.050M $4.510M $3.700M
YoY Change 18.63% -9.76%
Total Long-Term Liabilities $6.050M $4.510M $3.700M
YoY Change 18.63% -9.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.650M $1.880M $2.070M
Total Long-Term Liabilities $6.050M $4.510M $3.700M
Total Liabilities $8.700M $6.390M $5.780M
YoY Change 42.39% 3.68% 4.9%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.060M $6.770M $2.170M
YoY Change
Total Liabilities & Shareholders Equity $10.76M $13.16M $7.940M
YoY Change -0.46% 183.84% -14.53%

Cashflow Statement

Concept 2017 Q3 2017 Q2 2017
OPERATING ACTIVITIES
Net Income -$5.243M -$1.626M -$12.23M
YoY Change 73.31% -45.26% 13.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.200M -$2.090M -$8.717M
YoY Change -9.09% -6.28% 0.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $7.389M
YoY Change 1982.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K 0.000 7.389M
YoY Change -99.31% -100.0% -18.08%
NET CHANGE
Cash From Operating Activities -2.200M -2.090M -8.717M
Cash From Investing Activities
Cash From Financing Activities 60.00K 0.000 7.389M
Net Change In Cash -2.140M -2.090M -1.328M
YoY Change -134.24% 6.09% -528.32%
FREE CASH FLOW
Cash From Operating Activities -$2.200M -$2.090M -$8.717M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
9338068
CY2017 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.90
CY2017 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2017 us-gaap Operating Expenses
OperatingExpenses
11230682
CY2016 us-gaap Operating Expenses
OperatingExpenses
10544425
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-10544425
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-11230682
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15413610
CY2017 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
7137493
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15413610
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12350360
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12350360
CY2016 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
6951600
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1819431
CY2016Q1 us-gaap Net Income Loss
NetIncomeLoss
-3225409
CY2016 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
CY2016 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.15
CY2017 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14897885
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4948909
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4688252
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
1235
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
62595546
CY2017 evok Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm
P3Y11M8D
CY2016Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3787638
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
9294330
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14951036
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3592825
CY2016 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-268029
CY2017 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1005349
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-597615
CY2016 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9338068
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
3464929
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1706524
CY2016Q4 evok Warrant Liability
WarrantLiability
4095019
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 evok Warrant Liability
WarrantLiability
3701277
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1541
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
73202863
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71038655
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58809143
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2165749
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7941864
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4093189
CY2017 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
6519
CY2016 evok Financing Costs Related To Warrant Liability
FinancingCostsRelatedToWarrantLiability
533692
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
98742
CY2016 evok Stock Issued During Period Value Issuance Of Common Stock And Warrants
StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrants
8803036
CY2016 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
206825
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7254348
CY2017 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1399091
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-554014
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
1819431
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1706524
CY2016 us-gaap Paid In Kind Interest
PaidInKindInterest
120889
CY2017 evok Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
526315
CY2016 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
4500000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7389101
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
354855
CY2016 evok Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
13168803
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7389101
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9023658
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1327804
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
315916
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8691155
CY2016 us-gaap Interest Paid
InterestPaid
169813
CY2016 evok Fair Value Of Warrants Issued To Placement Agent
FairValueOfWarrantsIssuedToPlacementAgent
369863
CY2017 evok Reclassification Of Warrant Liability To Equity Due To Exercise Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToExerciseOfWarrants
1399091
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
116000
CY2017Q4 us-gaap Capital Leases Future Minimum Payments Due Current
CapitalLeasesFutureMinimumPaymentsDueCurrent
139000
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
628801
CY2017 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P2Y
CY2017 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2018-12-31
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
135000
CY2016Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
37463
CY2017Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5093920
CY2017 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2017 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2017 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2016 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2017 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
53061
CY2016 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2017 evok Lease Commencement Date
LeaseCommencementDate
2017-01-01
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p></div>
CY2017 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in a federally insured financial institution in excess of federally insured limits. The Company has established guidelines designed to maintain safety and liquidity, has not experienced any losses in such accounts and believes the exposure to significant risk to the cash balance is minimal.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company relies on a contract research organization (&#8220;CRO&#8221;) to manage the preparation and submission of the planned NDA.&nbsp;&nbsp;If this CRO is unable to continue the management of the NDA preparation, the delays could adversely affect the timing of the Company&#8217;s NDA submission with FDA.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#8217;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, if approved by FDA, and the development and/or commercialization of Gimoti could be materially and adversely affected. </p></div>
CY2016 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
34067
CY2016Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
5265764
CY2017 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0209
CY2016 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0193
CY2017 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock is entitled to one vote. The holders of the common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors of the Company.
CY2017 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
0
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3323876
CY2017 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.0039
CY2016 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P5Y29D
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2797561
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.29
CY2017 evok Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm
P4Y25D
CY2017 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
2.26
CY2016 evok Share Based Compensation Arrangements By Share Based Payment Award Options Outstanding Date Intrinsic Value
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsOutstandingDateIntrinsicValue
2.02
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.87
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.04
CY2017Q4 evok Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized For Employee Stock Purchase Plan
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedForEmployeeStockPurchasePlan
91934
CY2017 us-gaap Stock Issued During Period Shares Period Increase Decrease
StockIssuedDuringPeriodSharesPeriodIncreaseDecrease
220000
CY2017Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
135000
CY2016Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
99000
CY2017 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
75529
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y1M17D
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2131624
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1275624
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
72801
CY2017 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2016 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000
CY2017Q4 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2017Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2017 evok Minimum Age Of Employee To Participate In Defined Benefit Plan
MinimumAgeOfEmployeeToParticipateInDefinedBenefitPlan
P21Y
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
3700
CY2017 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2017Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2017Q4 evok Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
7900000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2017 evok Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant Liability Adjustment
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrantLiabilityAdjustment
-0.08
CY2016 evok Effective Income Tax Rate Reconciliation Fair Market Value Of Warrant Liability Adjustment
EffectiveIncomeTaxRateReconciliationFairMarketValueOfWarrantLiabilityAdjustment
0.06
CY2016 evok Effective Income Tax Rate Reconciliation Stock Issuance Costs
EffectiveIncomeTaxRateReconciliationStockIssuanceCosts
0.05
CY2017 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.03
CY2016 evok Effective Income Tax Rate Reconciliation Tax Credits Research And Development
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchAndDevelopment
0.03
CY2017 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
-0.33
CY2016 evok Effective Income Tax Rate Reconciliation Operating Loss And Tax Credits Other
EffectiveIncomeTaxRateReconciliationOperatingLossAndTaxCreditsOther
0.33
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.65
CY2017 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
-0.03
CY2016 evok Effective Income Tax Rate Reconciliation Deductible Expense Share Based Compensation And Other Permanent Items
EffectiveIncomeTaxRateReconciliationDeductibleExpenseShareBasedCompensationAndOtherPermanentItems
0.05
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
15900000
CY2017 evok Cumulative Minimum Change In Ownership Percentage For Limitation On Utilization Of Net Operating Loss Carry Forwards
CumulativeMinimumChangeInOwnershipPercentageForLimitationOnUtilizationOfNetOperatingLossCarryForwards
0.50
CY2016 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
0.9419
CY2017 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y29D
CY2017 evok Cumulative Change In Ownership Period
CumulativeChangeInOwnershipPeriod
P3Y
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3000000
CY2017 evok Percentage Of Taxable Income Offset By Tax Losses
PercentageOfTaxableIncomeOffsetByTaxLosses
0.80
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5052039
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
103000
CY2016Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
201000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
490000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
539000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
984047
CY2017Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1027594
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1961595
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1961595
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3072747
CY2017Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1261912
CY2017Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1544138
CY2017Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2349624
CY2017Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
216000
CY2016Q4 evok Deferred Tax Assets Tax Accruals And Other
DeferredTaxAssetsTaxAccrualsAndOther
130000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
809000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
870000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
809000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
870000
CY2017Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1961595
CY2017Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2017 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2017 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
770686
CY2017Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2017569
CY2017Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2717698
CY2017Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1631540
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1209570
CY2017Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
871979
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-1625969
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-5243061
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-308443
CY2017Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2017Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2017Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2017Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2017Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13528311
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15343325
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15351295
CY2017Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15368610
CY2017Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13528311
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15420954
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15351295
CY2017Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
15503583
CY2016Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2015076
CY2016Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2095149
CY2016Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1339343
CY2016Q4 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1502032
CY2016Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1137753
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
802655
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
830092
CY2016Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
822325
CY2016Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
198945
CY2016Q4 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-796560
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-2970498
CY2016Q3 us-gaap Net Income Loss
NetIncomeLoss
-3025281
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-1527343
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.45
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2016Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7168005
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7217577
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10614692
CY2016Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
12305360

Files In Submission

Name View Source Status
0001564590-18-004725-index-headers.html Edgar Link pending
0001564590-18-004725-index.html Edgar Link pending
0001564590-18-004725.txt Edgar Link pending
0001564590-18-004725-xbrl.zip Edgar Link pending
evok-10k_20171231.htm Edgar Link pending
evok-20171231.xml Edgar Link completed
evok-20171231.xsd Edgar Link pending
evok-20171231_cal.xml Edgar Link unprocessable
evok-20171231_def.xml Edgar Link unprocessable
evok-20171231_lab.xml Edgar Link unprocessable
evok-20171231_pre.xml Edgar Link unprocessable
evok-ex1021_515.htm Edgar Link pending
evok-ex231_6.htm Edgar Link pending
evok-ex311_8.htm Edgar Link pending
evok-ex312_10.htm Edgar Link pending
evok-ex321_7.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2018030718191233743011.jpg Edgar Link pending
g2018030718191328943012.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending